openPR Logo
Press release

Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration

04-16-2012 10:33 PM CET | Science & Education

Press release from: Proteros biostructures GmbH

Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.

Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry expertise.

Dr. Klaus Hinterding, Proteros CSO, stated: “We are very pleased to further deepen our existing relationship with Eisai by being selected as partner for this important program. We look forward to contributing to the success of Eisai’s research activities using our unique technology platform.

About Proteros:
Proteros is a privately held company, which provides services and proprietary technologies to support knowledge-driven drug discovery programs. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ capabilities with its unique technology platform and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan.

About Eisai:

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com/.

Proteros biostructures GmbH
Dr. Thomas Waldmann
Bunsenstrasse 7a
82152 Martinsried
Germany
Phone: +49 89 7007 61 – 0
E-Mail: business@proteros.com
Internet: www.proteros.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration here

News-ID: 218204 • Views: 6619

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and
Proteros has relocated to a tailor-made facility in Martinsried
Martinsried, October 24th 2011. Proteros biostructures GmbH is further extending its business capacities by moving into a new building in Munich-Martinsried, one of the leading Biotech locations in Germany. After a two-year planning period, Proteros has reached an important milestone in its development by centralizing all operations within a purpose-built facility. The 4,000 square-meter of laboratory and office space, worth a total of about 15 M €, has been optimally designed

All 5 Releases


More Releases for Eisai

Lennox-Gastaut Syndrome (LGS) Therapeutics Pipeline to Witness Significant Growt …
According to a new research report “Lennox-Gastaut Syndrome (LGS) - Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2018” published by Pharma Proff, LGS therapeutics currently exhibits a proliferating pipeline with eight active therapeutic candidates in different stages of development. LGS Pipeline Insights LGS is a rare and severe form of epilepsy that mostly affects individuals during infancy or early childhood. This syndrome has the tendency to develop between the age of one
Global Insomnia Market 2018 - Merck, Eisai, Meda Consumer Healthcare,Sanofi
Accord Market, recently published a detailed market research study focused on the “Insomnia Market” across the global, regional and country level. The report provides 360° analysis of “Insomnia Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Insomnia Market on the basis of
Global Epilepsy Drugs Market 2018 - UCB, Cephalon, Shire, Eisai, Pfizer
Eminent Market, recently published a detailed market research study focused on the "Epilepsy Drugs Market" across the global, regional and country level. The report provides 360° analysis of "Epilepsy Drugs Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Epilepsy Drugs industry, and estimates the future trend of Epilepsy Drugs market on
Global Serotonin Antagonists Market 2018 - Roerig, Pfizer, Eisai, Sanofi, Roche
Apex Market Reports, recently published a detailed market research study focused on the “Serotonin Antagonists Market” across the global, regional and country level. The report provides 360° analysis of “Serotonin Antagonists Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Serotonin Antagonists on
Gastroesophageal Reflux Disease Therapeutics Market 2017 - AstraZeneca, Eisai, P …
Apex Research, recently published a detailed market research study focused on the "Gastroesophageal Reflux Disease Therapeutics Market" across the global, regional and country level. The report provides 360° analysis of "Gastroesophageal Reflux Disease Therapeutics Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Gastroesophageal Reflux Disease Therapeutics industry, and estimates the future
Eisai Co. Ltd Cancer Drugs Clinical Pipeline Insight
“Eisai Co. Ltd Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Eisai Co. Ltd. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “31” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 15 cancer drugs by Eisai Co. Ltd. which